首页> 外文期刊>Cancer biology & therapy >Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
【24h】

Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer

机译:HER2和JAK / STAT-SOCS3信号通路与卵巢癌的临床病理特征与预后的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The study aims to explore the relationship between expressions of HER2 and JAK/STAT3-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer (OC). Methods: A total of 136 OC patients were collected. Immunohistochemistry was applied to measure the expressions of STAT3, p-STAT3, SOCS3, HER2 and p-HER2 in the tumor tissues and adjacent normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of HER2, SOCS3 and STAT3 and western blotting was applied for protein expressions of HER2, p-HER2, SOCS3, STAT3 and p-STAT3 in the tumor tissues and adjacent normal tissues. Flow cytometry was used for the cell apoptosis in the blank, afatinib (A), ruxolitinib (R) and afatinib + ruxolitinib (A + R) groups. Follow-up was performed to explore relationship of HER2, SOCS3, and STAT3 expressions with survival time of OC patients.
机译:目的:该研究旨在探讨HER2和JAK / STAT3-SOCS3信号通路和卵巢癌(OC)临床病理特征和预后的关系。 方法:收集136例OC患者。 施用免疫组织化学以测量肿瘤组织和相邻正常组织中的STAT3,P-STAT3,SOCS3,HER2和P-HER2的表达。 使用定量实时聚合酶链反应(QRT-PCR)检测HER2,SOCS3和STAT3和Western印迹的mRNA表达,在肿瘤中施用HER2,P-HER2,SOCS3,STAT3和P-STAT3的蛋白质表达 组织和相邻的正常组织。 流式细胞术用于坯料,AFATINIB(A),Ruxolitinib(R)和AFATINIB + Ruxolitinib(A + R)基团中的细胞凋亡。 进行了随访,以探索HER2,SOCS3和STAT3表达与OC患者的存活时间的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号